At Supply Side West 2017, WACKER is presenting new results on the effect of its nature-identical hydroxytyrosol HTEssence® on heart health.
After the incident at WACKER’s US production site in Charleston, Tennessee, already reported on, root-cause investigation work is now well underway.
In Q2 2017, Wacker Chemie AG achieved a slight increase in sales compared with the adjusted prior-year figure reflecting the deconsolidation of Siltronic and substantial growth in EBITDA versus Q1 2017.
In Q1 2017, Wacker Chemie AG continued to increase its sales and operating result compared with its adjusted figures of a year earlier and a quarter ago following the deconsolidation of Siltronic.
The WACKER Group (“WACKER”) is reducing its stake in Siltronic AG (“Siltronic”) from 51.8 percent to 30.8 percent.